Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Fineline Cube Aug 18, 2026
Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Fineline Cube Aug 18, 2026
Company Drug

Novo Nordisk’s Semaglutide for Weight Loss Accepted for Review by China’s NMPA

Fineline Cube Jun 5, 2023

Denmark-headquartered Novo Nordisk (NYSE: NVO) has announced that its market filing for the glucagon-like peptide-1...

Company Drug

Qilu Pharmaceutical Gains Temporary FDA Approval to Import Cisplatin Amid US Shortage

Fineline Cube Jun 5, 2023

Qilu Pharmaceutical, a China-based firm, has benefited from the effects of drug shortages in the...

Policy / Regulatory

CDE Releases 70th Batch of Generic Reference Preparations for Public Feedback

Fineline Cube Jun 5, 2023

The Center for Drug Evaluation (CDE) has released the 70th batch of chemical generic reference...

Company Drug

CStone Pharmaceuticals and Blueprint Medicines’ Ayvakit Wins FDA Approval for ISM Treatment

Fineline Cube Jun 5, 2023

Partners CStone Pharmaceuticals (HKG: 2616) and Blueprint Medicines have announced that the US FDA has...

Company Deals

Neurophth Biotechnology Partners with Sinopharm Group to Commercialize Gene Therapy NFS-01

Fineline Cube Jun 5, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced a strategic partnership with compatriot firm...

Company Drug

Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G

Fineline Cube Jun 2, 2023

Sirnaomics Ltd (HKG: 2257) has announced the first systemic dosing of a Phase I clinical...

Company Drug

CANbridge Pharmaceuticals’ Maralixibat Approved by NMPA for Alagille Syndrome

Fineline Cube Jun 2, 2023

China-based rare disease specialist CANbridge Pharmaceuticals Inc., (HKG: 1228) has announced receiving market approval from...

Company Deals Drug

Innovent Biologics Partners with Merck KGaA to Test KRAS Inhibitor Combo in NSCLC

Fineline Cube Jun 2, 2023

China-based Innovent Biologics (HKG: 1801) has announced a clinical study and supply agreement with German...

Company Deals

Shenzhen Abrobo Medical Robot Secures RMB 100 Million in Series A Financing for Robotic Development

Fineline Cube Jun 2, 2023

Shenzhen Abrobo Medical Robot Co, Ltd has reportedly raised RMB 100 million via a Series...

Company Drug

Akeso Biopharma’s Ebronucimab NDA Accepted for Review by China’s NMPA

Fineline Cube Jun 2, 2023

China-based Akeso Biopharma (HKG: 9926) has announced that the National Medical Products Administration (NMPA) has...

Company Deals

Eikon Therapeutics Inks Licensing Deals and Raises Funds for Drug Pipeline Expansion

Fineline Cube Jun 2, 2023

US biotech company Eikon Therapeutics has announced three in-licensing deals this week, one of which...

Company Deals

Sino Biopharmaceutical’s Subsidiary invoX Completes Additional Investment in pHion Therapeutics

Fineline Cube Jun 2, 2023

The UK-based invoX Pharma Ltd, a wholly-owned subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177),...

Company Deals

Ucello Therapeutics Secures RMB 150 Million in Series A+ Financing for CAR-T Cell Therapy

Fineline Cube Jun 2, 2023

Ucello Therapeutics, a developer of allogeneic universal chimeric antigen receptor (CAR)-T cell therapies based in...

Company Deals

Eversana Forms Strategic Alliance with China Resource Pharmaceutical for Healthcare Expansion

Fineline Cube Jun 2, 2023

US-based commercial services provider Eversana has announced a strategic alliance with China Resource Pharmaceutical Commercial...

Company Deals

Adcendo ApS Expands Partnership with Duality Biologics for Two Additional ADCs

Fineline Cube Jun 2, 2023

Denmark-based Adcendo ApS has announced the expansion and exercise of options to two additional antibody...

Policy / Regulatory

State Council Mandates Enhanced Oversight of Medical Insurance Funds Utilization

Fineline Cube Jun 1, 2023

The State Council has issued the “Implementation Opinions on Strengthening the Normalization Supervision of the...

Policy / Regulatory

NMPA Issues Procedures for Enhancing Children’s Medication Information in Drug Inserts

Fineline Cube Jun 1, 2023

The National Medical Products Administration (NMPA) has released the “Procedures for Adding Children’s Medication Information...

Company Drug

Jiangsu Hengrui Medicine’s SHR-1905 and SHR7280 Receive NMPA Clinical Trial Approvals

Fineline Cube Jun 1, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals from...

Company Drug

Brii Biosciences Initiates Phase I Study for BRII-297 in Australia

Fineline Cube Jun 1, 2023

China’s Brii Biosciences (HKG: 2137) has announced the first patient dosing in a Phase I...

Company Drug

AIM Vaccine’s Omicron BA.5 mRNA Vaccine Shows 73.16% Efficacy in China Trial

Fineline Cube Jun 1, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has revealed the protective efficacy of its Omicron...

Posts pagination

1 … 562 563 564 … 709

Recent updates

  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
  • Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
  • Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors
  • CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.